Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs

– Expected use of approximately $25 million in first quarter of 2025 intended to preserve approximately 200,000 ADSs held as treasury shares

COPENHAGEN, Denmark, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its Board of Directors has authorized the Company to use approximately $25 million to fund a share repurchase program and net settle certain RSUs.